
Shares of Orthocell OCC.AX rise 15.4% to A$1.500, their highest levels since Jan 6
The regenerative medicine firm says that it plans to enter key markets such as Canada and Thailand, among others, in CY2025
Orthocell recently submitted its USFDA regulatory application for the clearance to distribute its nerve drug Remplir in the $1.6 bln (A$2.55 bln) U.S. market commercially
Co expects approval in March/April 2025
About 3.4 mln shares trade hands, 1.9 times the 30-day average of 1.8 mln
Stock rose 230.5% in 2024
(1 Australian dollar = $0.6266)
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))